A Naturalistic Study of High-dose Clozapine Treatment in Refractory Schizophrenia Using a Within-subject Design
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Objective：Clozapine is the treatment of choice for treatment-resistant schizophrenia. However, some patients with clozapine treatment at the typical recommended dosage (300-600 mg/day) continue to experience significant symptoms. This naturalistic follow-up study evaluated the efficacy and safety of clozapine at a higher than typical dose in patients with refractory schizophrenia. Methods：Thirteen of 19 subjects with refractory schizophrenia completed this prospective, open-label trial. The primary efficacy measure was the Positive and Negative Syndrome Scale for Schizophrenia (PANSS), and safety measures included the Simpson Angus Rating Scale (SAS) and recording of adverse events. Repeated measures ANOVA was used to evaluate whether a higher dose of clozapine resulted in further symptom improvement. Results：No improvement was found in overall psychopathology, except for PANSS general psychopathology scores, when going from 600 mg/day to the higher dose of clozapine, although the higher dose was well tolerated. Conclusions：This open study suggests that clozapine at a higher dosage does not improve overall symptoms more than 600 mg/day, although has comparable tolerability. Augmentation or determination of other possible factors related to refractoriness should be considered to improve symptoms in cases in which typical dosage clozapine does not fully elicit a response. The results of this study must be confirmed with a larger sample size and controlled trials in the near future.
Abstract
Objective：Clozapine is the treatment of choice for treatment-resistant schizophrenia. However, some patients with clozapine treatment at the typical recommended dosage (300-600 mg/day) continue to experience significant symptoms. This naturalistic follow-up study evaluated the efficacy and safety of clozapine at a higher than typical dose in patients with refractory schizophrenia. Methods：Thirteen of 19 subjects with refractory schizophrenia completed this prospective, open-label trial. The primary efficacy measure was the Positive and Negative Syndrome Scale for Schizophrenia (PANSS), and safety measures included the Simpson Angus Rating Scale (SAS) and recording of adverse events. Repeated measures ANOVA was used to evaluate whether a higher dose of clozapine resulted in further symptom improvement. Results：No improvement was found in overall psychopathology, except for PANSS general psychopathology scores, when going from 600 mg/day to the higher dose of clozapine, although the higher dose was well tolerated. Conclusions：This open study suggests that clozapine at a higher dosage does not improve overall symptoms more than 600 mg/day, although has comparable tolerability. Augmentation or determination of other possible factors related to refractoriness should be considered to improve symptoms in cases in which typical dosage clozapine does not fully elicit a response. The results of this study must be confirmed with a larger sample size and controlled trials in the near future.
참고문헌 (32)
- Dixon LB, "Conventional antipsychotic medications for schizophrenia", Schizophr Bull, 21, pp.567~577 (1995)
- Kane J, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine", Arch gen Psychiatry, 45, pp.789~796 (1988)
- Lieberman JA, "Clozapine: guidelines for clinical management", J Clin Psychiatry, 50, pp.329~338 (1989)
- Cho HS, "Agranulocytosis and neutropenia in clozapine-treated patients", Korean J Psychopharmacol, 10, pp.166~172 (1999)
- Revicki DA, "Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia", Schizophr Res, 35, pp.s101~s109 (1999)
- Lee HS, "Costeffectiveness of clozapine treatment for patients with refractory schizophrenia", Korean J Psychopharmacol, 9, pp.27~34 (1998)
- Bitter I, "Olanzapine versus clozapine in treatment- resistant or treatment-intolerant schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 28, pp.173~180 (2004)
- Rodriguez-Perez V, "Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.1055~1062 (2002)
- Lee H-S, "Efficacy of risperidone in treatment-resistant patients with chronic schizophrenia", J Psychopharmacol, 8, pp.60~68 (1997)
- Sharif ZA, "Treatment refractory schizophrenia: how should we proceed?", Psychiatr Q, 69, pp.263~281 (1998)
- McEvoy JP, "Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment", Am J Psychiatry, 163, pp.600~610 (2006)
- Taylor CG, "An open trial of risperidone augmentation of partial response to clozapine", Schizophr Res, 48, pp.155~158 (2001)
- Gupta S, "Olanzapine augmentation of clozapine", Ann Clin Psychiatry, 10, pp.113~115 (1998)
- Kontaxakis VP, "Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review", Eur Psychiatry, 20, pp.409~415 (2005)
- Simpson GM, "Double-blind study of clozapine dose response in chronic schizophrenia", Am J Psychiatry, 156, pp.1744~1750 (1999)
- Kwon JS, "Clinical studies of risperidone in Korea", Korean J Psychopharmacol, 14, pp.128~139 (2003)
- Association AP, "Diagnostic and statistical manual of mental disorder, 4th ed (DSM-IV)" (1994), American Psychiatric Press
- Schulte P, "What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatmentrefractory schizophrenia", Clin Pharmacokinet, 42, pp.607~618 (2003)
- Ereshefsky L, "Clozapine: an atypical antipsychotic agent", Clin Pharm, 8, pp.691~709 (1989)
- Maccall C, "Clozapine: more than 900 mg", day may be needed, 2009, pp.23, 206~210
- Maeda H, "Clinical effects of quetiapine fumarate against treatment- resistant schizophrenia", Jpn J Clin Psychopharmacol, 6, pp.653~ (1999)
- Ciapparelli A, "Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study", J Clin Psychiatry, 61, pp.329~334 (2000)
- Hosak L, "Antiepileptic drugs in schizophrenia: a review", Eur Psychiatry, 17, pp.371~378 (2002)
- Chan J, "Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence", J Psychopharmacol, 21, pp.657~664 (2007)
- Daniel DG, "Treatment of the refractory schizophrenic patient", J Clin Psychiatry, 59(1), pp.s13~s19 (1998)
- Hellewell JS, "Treatment-resistant schizophrenia: reviewing the options and identifying the way forward", J Clin Psychiatry, 60(23), pp.s14~s19 (1999)
- Kane JM, "Clinical efficacy of clozapine in treatmentrefractory schizophrenia: an overview", Br J Psychiatry Suppl, 17, pp.41~45 (1992)
- Lee HS, "Therapeutic predictors of clozapine treatment in patients with refractory schizophrenia", Korean J Psychopharmacol, 10, pp.32~39 (1999)
- Meltzer HY, "The pharmacoeconomics of clozapine: a review", J Clin Psychiatry, 55(b), pp.s161~s165 (1994)
- Jann MW, "Pharmacokinetics and pharmacodynamics of clozapine", Clin Pharmacokinet, 24, pp.161~176 (1993)
- 김진훈, "한국어판 정신분열병 삶의 질 척도의 개발과 PANSS와의 관련성", 신경정신의학, 45(5), pp.401~410 (2006), 대한신경정신의학회
- Miller DD, "The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia", Ann Clin Psychiatry, 8, pp.99~109 (1996)